(Q40213093)

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

18 September 2017

2 references

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. (English)

1 reference

18 September 2017

1 reference

6

Fazlul H Sarkar

0 references

author name string

Basil F El-Rayes

1

1 reference

18 September 2017

Shadan Ali

2

1 reference

18 September 2017

Ifrah F Ali

3

1 reference

18 September 2017

Philip A Philip

4

1 reference

18 September 2017

James Abbruzzese

5

1 reference

18 September 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

18 September 2017

1 reference

18 September 2017

66

1 reference

18 September 2017

10553-10559

1 reference

18 September 2017

21

1 reference

Retraction: Potentiation of the Effect of Erlotinib by Genistein in Pancreatic Cancer: The Role of Akt and Nuclear Factor-κB

18 September 2017

0 references

cites work

Mechanisms of cancer chemoprevention by soy isoflavone genistein

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Transcription factor NF-kappaB: a sensor for smoke and stress signals

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

EGFR enhances Survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Nuclear factor-kappa B and cancer: its role in prevention and therapy

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

The immunohistochemical expressions of epidermal growth factors, epidermal growth factor receptors and c-erbB-2 oncoprotein in human pancreatic cancer.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

The role of survivin as a new target of diagnosis and treatment in human cancer

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Developments in the systemic therapy of pancreatic cancer

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Dietary flavonoids: bioavailability, metabolic effects, and safety

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Increasing complexity of Ras signaling.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Cancer statistics, 2006

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

The epidermal growth factor receptor in human pancreatic cancer

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Untangling the ErbB signalling network

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Soy isoflavone supplementation in healthy men prevents NF-kappa B activation by TNF-alpha in blood lymphocytes

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1158/0008-5472.CAN-06-2333

Identifiers

DOI

10.1158/0008-5472.CAN-06-2333

1 reference

18 September 2017

1 reference